A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors

Summary

To characterize safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of QEQ278 in adult patients with advanced/metastatic non-small cell lung cancer, esophageal squamous cell carcinoma, renal cell carcinoma, and human papilloma virus associated head and neck squamous cell carcinoma.

Timeline

Start

2023-04-04

Primary completion

2026-01-26

Completion

2026-01-26

Outcome

Outcome not reported

Stopped (Business): “Business decision and not related to safety concerns”

Drugs

Indications